Resverlogix is uniquely positioned in the cardiovascular disease (CVD) market. The NexVas platform encompasses three programs: NexVas Plaque Regression (NexVas PR), NexVas Vascular Inflammation (NexVas VI) and NexVas Alzheimer's Disease (NexVas AD).
NexVas™ Platform
NexVas PR
Novel small molecules that enhance ApoA-I for atherosclerosis plaque regression.
NexVas VI
Novel small molecules that inhibit markers for vascular inflammation for plaque stabilization.
NexVas AD
Novel small molecules that enhance ApoA-I for stabilization and regression of Beta Amyloid Plaque (AD).
NexVas AD
Novel small molecules that enhance ApoA-I for stabilization and regression of Beta Amyloid Plaque (AD).
NexVas AD
Novel small molecules that enhance ApoA-I for stabilization and regression of Beta Amyloid Plaque (AD).
NexVas AD
Novel small molecules that enhance ApoA-I for stabilization and regression of Beta Amyloid Plaque (AD).
